Quarterly report · Q2
7733.TEDINET S100PO2O
Period2022-04-01 → 2022-09-30
Filed2022-11-21
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Amends S100PKO6.
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥417.1bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥224.8bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥750.1bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥360.1bn | 2021-04-01 → 2021-09-30 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥193.3bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥93.6bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥49.1bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥70.7bn | 2021-04-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥44.7bn | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥89.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥47.3bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥141.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥68.4bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥43.0bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥66.8bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥42.0bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥115.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥62.4bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥43.7bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥66.9bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥42.0bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥62.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥43.8bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥1.49T | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.36T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.19T | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥842.0bn | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥846.6bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥644.1bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥511.4bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥447.2bn | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥395.5bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥643.0bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥510.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥446.1bn | at 2021-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥255.8bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥297.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥302.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥193.4bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥6.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥169.7bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥68.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥15.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥71.0bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥50.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥35.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥40.7bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥44.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥52.5 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥32.97 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥90.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥48.53 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥34 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥52.45 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥32.93 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥90.17 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥48.51 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥33.98 | 2021-07-01 → 2021-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 43.3% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 37.6% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 37.6% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥4.3bn |
| jpcrp040300-q2r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥68.9bn |
| jpcrp040300-q2r_E02272-000Otherreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥788m |
| jpcrp040300-q2r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥29.8bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥97.9bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥20.1bn |
| jpcrp040300-q2r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥61.6bn |
| jpcrp040300-q2r_E02272-000Otherreportable segment | segment profit | 2021-04-01 → 2021-09-30 | −¥1.1bn |
| jpcrp040300-q2r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥30.3bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥90.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 766
| Item | Context | Value | Unit |
|---|---|---|---|
| Impairment losses pl IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1775000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_ReconcilingItemsMember | 478000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration | 2253000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 258472000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 152935000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember | 5653000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 417060000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Sales to external customers IFRS | CurrentYTDDuration | 417060000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember | 162000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_ReportableSegmentsMember | 162000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_ReconcilingItemsMember | -162000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration | － | JPY |
| Net sales IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 258472000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 152935000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember | 5815000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_ReportableSegmentsMember | 417222000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_ReconcilingItemsMember | -162000000 | JPY |
| Net sales IFRS | CurrentYTDDuration | 417060000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 68899000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 29788000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember | -788000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 97899000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | -4296000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 93603000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 1764000000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 6046000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 89321000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 371000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_ReportableSegmentsMember | 371000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration | 371000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 19114000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 9639000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember | 857000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_ReportableSegmentsMember | 29610000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration_ReconcilingItemsMember | 2973000000 | JPY |
| Depreciation and amortization operating expenses IFRS | CurrentYTDDuration | 32583000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 332000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 397000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000OtherReportableSegmentMember | 3000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_ReportableSegmentsMember | 732000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration | 732000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書（2022年11月21日付け訂正報告書の添付インラインXBRL） | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |